Investing is a bit like an Ellery Queen mystery. If you can follow the clues you should find what you're seeking - upside.» Read More
*Elan surges after $8.6 bln takeover offer from Perrigo. Shares in Irish drugmaker Elan jumped 8.3 percent after U.S. peer Perrigo agreed to buy the firm for $8.6 billion, sparking a rally in health care stocks, with Shire up 2.1 percent and AstraZeneca up 1.2 percent. France's Havas soared 5.7 percent and UK's WPP added 1.7 percent.
Shares in Irish drugmaker Elan jumped 7.9 percent after U.S. peer Perrigo agreed to by the firm for $8.6 billion. Publicis, whose shares were halted on Monday, unveiled over the weekend a plan to merge with rival Omnicom in a deal worth $35.1 billion.
U.S. generic drugmaker Perrigo agreed to buy fellow drug company Elan for $8.6 billion on Monday in a deal that will hand it royalty rights from a blockbuster treatment and tax savings from being domiciled in Ireland.
*Perrigo to pay $6.25 per share in cash, $10.25 in stock. DUBLIN, July 29- U.S. generic drugmaker Perrigo agreed to buy fellow drug company Elan for $8.6 billion on Monday in a deal that will hand it royalty rights from a blockbuster treatment and tax savings from being domiciled in Ireland.
WASHINGTON, July 23- A U.S. Supreme Court ruling giving regulators the right to sue drugmakers for agreements that delay sale of cheaper generic pharmaceuticals should deter some of the most egregious deals and allow the agency to better fight others, Federal Trade Commission Chairwoman Edith Ramirez told lawmakers on Tuesday.
WASHINGTON, July 23- A recent U.S. Supreme Court ruling giving regulators the right to sue drugmakers for agreements that delay cheaper generic versions of their products should deter some of the most egregious deals and allow the agency to better fight others, Federal Trade Commission Chairwoman Edith Ramirez told lawmakers on Tuesday.
WASHINGTON, June 17- The U.S. Supreme Court ruled on Monday regulators can challenge deals between brand-name drug companies and generic rivals that delay cheaper medicines from going on sale, which regulators say increase costs to consumers by billions of dollars.
Perrigo CEO Joe Papa discusses the biotech industry, the state of the consumer and why Mucinex is going to be a big winner for his company.
As the economy stalled, many people opted for store brand medicines. But as the economy improves, will the trend reverse?
The Forensic Accounting ETF launches today. The fund spotlights a concept that is often woefully overlooked.
ALLEGAN, Mich.-- Perrigo Co., which makes store-brand over-the-counter drugs and infant formulas, said Wednesday that it received approval from the U.S. Food and Drug Administration to market an over-the-counter nicotine product similar to Nicorette mini lozenges.
*Receives FDA approval to market mini nicotine lozenges.
You’ve heard about all those big stocks that you should buy, but the pros say there are plenty of mid-size names that belong on your radar too.
Perrigo CEO Joseph Papa appeared on Wednesday's "Mad Money."
Perrigo CEO, Joseph Papa discusses his company's 11% Q2 profit rise, and its outlook on growth, with Mad Money's Jim Cramer.
A breakdown of better-than-expected earnings from the generic drug maker, with Joseph Papa, Perrigo CEO.
A lot of people aren’t doing their homework and those people are losing money.
When it comes to combating financial markets that all seem to move in unison, the options are getting so limited that some are questioning whether stock picking is a dying art.
Cramer and his researcher, Nicole Urken, discuss why homework—particularly during earnings season—remains important to recognizing the stock winners of the coming years.
Joseph Papa sits down with Cramer and explains why things are looking good for the private label drug maker.